glp-1 receptor agonist and dpp-4 inhibitor combination contraindicated versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes DPP-4 INHIBITORS - Dipeptidyl Peptidase-4
Description
a sulfonylurea)
Subsequently, the receptor is taken up by endosomes, where it can either continue its signaling intracellularly, be recycled to the cell surface (resensitization) or undergo lysosomal degradation
Physiological Reviews , 87(4), 14091439
Cureus, 15(7), e42153
First submitted to a journal in 1989, the article was finally published in 1992
